About G.C. (Koen) de Waard
Introduction
Koen is currently researching the prediction of immune responses post-vaccination against SARS-CoV-19 using pharmacokinetic and pharmacodynamic modelling. During the COVID-19 pandemic, the immune response after vaccinations was studied. With this data, a model will be developed to predict the immune response in certain populations, for instance immunocompromised patients. The resulting models could be of use in the preparation of possible future pandemics.
Furthermore, Koen is researching the optimization of latency reversal agents (LRA) dosing in HIV. Currently, in clinical trials the LRA's are dosed based on previous published in vitro, preclinical or ex vivo studies. To study the dose-response relationships and possibly optimize the dosing of these LRA's, PK-PD models will be developed.
Furthermore, Koen is researching the optimization of latency reversal agents (LRA) dosing in HIV. Currently, in clinical trials the LRA's are dosed based on previous published in vitro, preclinical or ex vivo studies. To study the dose-response relationships and possibly optimize the dosing of these LRA's, PK-PD models will be developed.
Field(s) of expertise
- Pharmacometrics
- Pharmacokinetics
- Pharmacydynamics
Education and career
Koen de Waard studied bio-pharmaceutical sciences as bachelor at the University of Leiden and continued with the master pharmacy in Leiden. He obtained his PharmD degree in 2024. He’s currently researching as part of his PhD the prediction of immune responses post-vaccination by using pharmacokinetic (PK) and pharmacodynamic (PD) modelling as a tool for pandemic preparedness. Additionally, he is using PK-PD modelling to research optimization of latency reversal agent dosing in the pursuit of an HIV cure.
Publications
Other positions
- Databasemanager at retroperitoneal fibrosis (RPF) expertise center, Albert Schweitzer Hospital, Dordrecht.
